CB1R hyperactivation is associated with increased hepatic steatosis and fibrogenesis, while its antagonism, both centrally and peripherally, has demonstrated protective effects in preclinical models, including reductions in steatosis, inflammation, and fibrosis. The gene discussed is CNR1; the disease is Hepatic steatosis.